Please use this identifier to cite or link to this item:
|ER alpha-independent NRF2-mediated immunoregulatory activity of tamoxifen
Càncer de mama
|Elsevier Masson s.r.l.
|Sex differences in immune-mediated diseases are linked to the activity of estrogens on innate immunity cells, including macrophages. Tamoxifen (TAM) is a selective estrogen receptor modulator (SERM) used in estrogen receptor-alpha (ER alpha)-dependent breast cancers and off-target indications such as infections, although the immune activity of TAM and its active metabolite, 4-OH tamoxifen (4HT), is poorly characterized. Here, we aimed at investigating the endocrine and immune activity of these SERMs in macrophages. Using primary cultures of female mouse macrophages, we analyzed the expression of immune mediators and activation of effector functions in competition experiments with SERMs and 17 beta-estradiol (E2) or the bacterial endotoxin LPS. We observed that 4HT and TAM induce estrogen antagonist effects when used at nanomolar concentrations, while pharmacological concentrations that are reached by TAM in clinical settings regulate the expression of VEGF alpha and other immune activation genes by ER alpha- and G protein-coupled receptor 1 (GPER1)-independent mechanisms that involve NRF2 through PI3K/Akt-dependent mechanisms. Importantly, we observed that SERMs potentiate cell phagocytosis and modify the effects of LPS on the expression of inflammatory cytokines, such as TNF alpha and IL1 beta, with an overall increase in cell inflammatory phenotype, further sustained by potentiation of IL1 beta secretion through caspase-1 activation.
|Reproducció del document publicat a: https://doi.org/10.1016/j.biopha.2021.112274
|It is part of:
|Biomedicine & Pharmacotherapy, 2021, vol.144, num. 112274
|Appears in Collections:
|Publicacions de projectes de recerca finançats per la UE
Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
Files in This Item:
This item is licensed under a Creative Commons License